Stay updated with breaking news from Alpine Immune Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PD-1 and PD-L1 inhibitors clinical trial pipeline constitutes 180+ key companies continuously working towards developing 200+ PD-1 and PD-L1 inhibitors drugs, analyzes DelveInsight LAS
EQS-News: EVOTEC SE / Key word(s): Quarter Results Evotec SE reports results for the first nine months 2022 and provides corporate up...
News, features, and commentary about cancer-related issues
The second patient who died in the Phase 1 test of Alpine Immune Sciences cancer drug, davoceticept, reportedly suffered the same cardiovascular complication as the first patient. The biotech company is stopping enrollment in two clinical tests of the drug and assessing all participants in the studies.
Inovio Pharmaceuticals and their current pipeline, science, technology and the advantages to the DNA platform are reviewed. Read the analysis here.